T. Brasel

The Prophylactic and Therapeutic Efficacy of the Broadly Active Antiviral Ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a Mouse Model of Lethal Ebola Virus Infection

This study evaluates the efficacy of EIDD-1931, a ribonucleoside analog, in preventing and treating lethal Ebola virus infection in mice.

A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques

A synthetic peptide vaccine targeting SARS-CoV-2 nucleocapsid protein protected rhesus macaques from viral challenge, reducing pneumonia and viral load.

Cell-type apoptosis in lung during SARS-CoV-2 infection

This study investigates cell-type apoptosis in lung tissues during SARS-CoV-2 infection, finding both intrinsic and extrinsic apoptotic pathways are activated, while some cell types remain refractory to infection.

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

The paper identifies SC31, a potent SARS-CoV-2 neutralizing antibody, and shows that its Fc-mediated effector functions are critical for its therapeutic efficacy in vivo.

Anti-IL-6 versus Anti-IL-6R BlockingAntibodies to Treat Acute Ebola Infection inBALB/c Mice: Potential Implications forTreating Cytokine Release Syndrome

This study shows that early IL-6 neutralization with an anti-IL-6 mAb improves outcomes in Ebola-infected mice, suggesting potential benefits for treating cytokine release syndrome.

An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors' CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

The paper identifies a conserved Ebola Zaire epitope that provides protection in mice and suggests its potential application in COVID-19 vaccine design.